Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultrase MT12 in children with cystic fibrosis and pancreatic insufficiency
NCT00880100Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Apr 2009
- Primary completion
- Nov 2009
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pancrelipase in cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI), sponsored by Forest Laboratories. Primary endpoint: Percentage of Patients With Control of Steatorrhea. Started Apr 2009; status: completed.
02
Drugs
pancrelipase
03
Conditions
cystic fibrosis (CF)exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT00880100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00880100.